Volume 7, Issue 1, March 2019, Page: 12-22
Epidemiological Status of Bacterial Meningitis Disease Following the Introduction of the Meningococcal A Conjugate Vaccine in the African Meningitis Belt
Andre Arsene Bita Fouda, Family Health Reproductive, Immunization Vaccine Development, World Health Organization, Brazzaville, Congo
Received: May 16, 2019;       Accepted: Jun. 25, 2019;       Published: Jul. 16, 2019
DOI: 10.11648/j.iji.20190701.13      View  492      Downloads  113
Bacterial meningitis disease is a burden in the African meningitis belt. Before 2010, Neisseria meningitidis serogroup A (Neisseria meningitidis A) was the predominant pathogen causing about 90 percent of meningitis epidemics in Africa. The meningococcal A conjugate vaccine (MACV) protecting against Neisseria meningitidis A was introduced since 2010. The purpose of this quantitative study was to determine the magnitude and fatality of meningitis bacterial disease in Africa following the introduction of MACV from 2010 and 2017. An interrupted time series design and nonprobability sampling were used. Secondary data issued of meningitis enhanced surveillance were retrieved from World Health Organization database. The binomial negative regression and Pearson’s Chi-Square tests were used. The study found that after the MACV introduction there was a 39% decline of incidence rate of meningitis suspected cases (IRR 0.61, 95% CI 0.48 – 0.79, p < .001) and 99% decline of the risk of Neisseria meningitidis A (RR 0.01, 95% CI 0.08-0.013). There was a difference in the meningitis CFR before and after MACV introduction in 21 out of the 26 countries of African meningitis belt. After the introduction of MACV, there was a 46% decline in risk to report high CFR (>10%) after the MACV immunization (RR 0.547, 95% CI 0.40 – 0.74). There was a 49% decline of fatal meningitis (IRR 0.51, 95% CI 0.41 – 0.68, p < .001). After 2010, Neisseria meningitidis A declined and S. Pneumoniae, Neisseria meningitidis W135, Neisseria meningitidis C, Neisseria meningitidis X, and Hib became predominant. Between 2010 and 2017 Neisseria meningitidis all serogroups concerned remained higher the other pathogens 15,885 (62.06%) Vs 25,596. The study showed that following the MACV introduction despite the dramatic reduction of Neisseria meningitidis A, meningococcal meningitis bacterial disease remains a major public health problem.
Meningitis, Neisseria meningitidis, Meningococcal a Conjugate Vaccine, African Meningitis Belt, Crude Fatality Rate
To cite this article
Andre Arsene Bita Fouda, Epidemiological Status of Bacterial Meningitis Disease Following the Introduction of the Meningococcal A Conjugate Vaccine in the African Meningitis Belt, International Journal of Immunology. Vol. 7, No. 1, 2019, pp. 12-22. doi: 10.11648/j.iji.20190701.13
Copyright © 2019 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
World Health Organization. Meningococcal meningitis, https://www.who.int/en/news-room/fact-sheets/detail/meningococcal-meningitis; 2018 [assessed 23 March 2019].
Centers for Disease Control and Prevention. An update on global partners reaching the ultimate goal of eliminating epidemic meningitis as a public health concern in Africa, http://www.cdc.gov/globalhealth/stories/meningitis.htm; 2015 [Accessed 1 May 2019].
Greenwood B. Meningococcal meningitis in Africa. Transactions of the Royal Society of Tropical Medicine and Hygiene 1999; 93 (4), 341-353. https://doi:10.1016/S0035-9203 (99) 90106-2.
Lapeyssonnie L. Cerebrospinal meningitis in Africa (in French), https://apps.who.int/iris/bitstream/handle/10665/72037/bulletin_supp%20_Vol28.pdf?sequence=1&isAllowed=y; 1963 [accessed 5 May 2019].
Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009); 27 (S2), B51-63. https://doi:10.1016/j.vaccine.2009.04.063.
Stephens DS, Greenwood B, Brandzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 2007; 369 (9580), 2196–2210. https://doi:10.1016/S0140-6736 (07) 61016-2.
World Health Organization. Global Health Observatory (GHO) data: Meningococcal meningitis, http://www.who.int/gho/epidemic_diseases/meningitis/en/2019; [accessed 5 May 2019].
Centers for Disease Control and Prevention. Working to eliminate epidemic meningitis in Sub-Saharan Africa, http://www.cdc.gov/ncird/div/DBD/newsletters/2012/summer/mening.html; 2012 [accessed 4 May 2019].
Collard JM., Issaka B, Zaneidou M, Hugonnet S, Nicolas P, Taha MK et al. Epidemiological changes in meningococcal meningitis in Niger from 2008 to 2011 and the impact of vaccination. BioMed Central Infectious Diseases 2013. 13, 576. https://doi:10.1186/1471-2334-13-576.
Djingarey MH, Barry R, Bonkoungou M, Tiendrebeogo S, Sebgo R, Kandolo D, et al. Effectively introducing a new meningococcal A conjugate vaccine in Africa: The Burkina Faso experience. Vaccine 2012; 30 (S2): B40-45. https://doi:10.1016/j.vaccine.2011.12.073.
Novak RT, Kambou JL, Diomandé FVK, Tarbangdo TF, Ouédraogo-Traoré R, Sangaré L, et al. Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data. Lancet Infectious Diseases 2012; 12, 757–764. https://doi:10.1016/s1473-3099 (12) 70168-8.
Daugla DM, Gami JP, Gamougam K, Naibei N, Mbainadji L, Narbé M, et al. Effect of a serogroup A meningococcal conjugate vaccine (PsA–TT) on serogroup A meningococcal meningitis and carriage in Chad: A community study. Lancet 2013; 383 (9911), 40–47. https://doi:10.1016/S0140-6736 (13) 61612-8.
Trotter CL, Lingani C, Katya F, Cooper LV, Bita A, Tevi-Benissan C, et al. The impact of MenAfriVac® in nine countries of the African meningitis belt, 2010-2015: An analysis of surveillance data. Lancet Infectious Disease 2017; 17, (S1473-3099) 30301-30308. https://doi:10.1016/S1473-3099 (17) 30301-8.
Kristiansen PA, Diomandé F, Ky BA, Sanou I, Ouédraogo AS., Ouédraogo R, et al. Impact of the Serogroup A Meningococcal Conjugate Vaccine, MenAfriVac®, on Carriage and Herd Immunity. Clinical Infectious Diseases 2013; 56 (3), 354-363. doi:10.1093/cid/cis892.
Diallo AO, Soeters HE, Medah I, Ouédraogo-Traoré R, Sangaré L, Bicaba B, et al. Evaluation of meningococcal serogroup A conjugate vaccine impact on meningitis epidemics in Burkina Faso: A five-year (2011-2015) follow-up analysis. PLoS One 2017; 12 (11), e0187466. https://doi:10.1371/journal.pone.0187466.
Diomandé FV, Djingarey MH, Daugla DM, Novak RT, Kristiansen PA, Collard JM, et al. Public health impact after the introduction of PsA-TT: The first 4 years. Clinical Infectious Diseases 2015; 61 (S5), S467-472. https://doi:10.1093/cid/civ499.
LaForce FM, Djingarey M, Viviani S, Preziosi MP. Successful African introduction of a new Group A meningococcal conjugate vaccine: Future challenges and next steps. Vaccines & Immunotherapeutics 2017; 14 (5), 1098–1102. https://doi:10.1080/21645515.2017.1378841.
Lingani C, Bergeron-Caron C, Stuart JM, Fernandez K, Djingarey MH, Ronveaux O, et al. Meningococcal meningitis surveillance in the African meningitis belt, 2004-2013. Clinical Infectious Diseases 2015; 61 (S5), S410-415. https://doi:10.1093/cid/civ597.
Sambo L, Chan M, Davis S, Lake A, Berkley CP, Elias CJ. A vaccine meets its promise: success in controlling epidemic meningitis in Sub-Saharan Africa. Clinical Infectious Diseases 2015; 61 (S5), S387–388. https://doi:10.1093/cid/civ490.
Stuart JM. Impact of serogroup A meningococcal conjugate vaccine for Africa. Human Vaccines & Immunotherapeutics 2018; 14 (5), 1116–1117. https://doi:10.1080/21645515.2017.1412022.
Fall A, Fouda Bita A, Lingani C, Djingarey M, Tevi-Benissan C, Preziosi MP, et al. Elimination of Epidemic Meningitis in the African Region: Progress and Challenges: 2010-2016. J Immunol Sci 2018; S (006): 41–45.
LaForce FM, Okwo-Bele JM. Eliminating Epidemic Group A meningococcal meningitis in Africa through a new vaccine. Health Affairs 2011; 30 (6), 1049-1057. https://doi:10.1377/hlthaff.2011.0328.
Mueller JE. Conjugate vaccine introduction in the African meningitis belt: meeting surveillance objectives. Tropical Medicine & International Health 2013; 18 (1), 58-64. https://doi:10.1111/tmi.12009.
Carod AFJ. Meningococcal meningitis: vaccination outbreak response and epidemiological changes in the African meningitis belt. International Health 2015; 7 (4): 226-227. https://doi:10.1093/inthealth/ihv025.
Obaro SK, Habib AG. Control of meningitis outbreaks in the African meningitis belt. Lancet Infectious Diseases 2016; 16 (4), 400-402. https://doi:10.1016/S1473-3099 (16) 00121-3.
Funk A Uadiale K Kamau C Caugant DA Ango U Greig J. Sequential outbreaks due to a new strain of Neisseria meningitidis serogroup C in northern Nigeria, 2013–14. PLoS Curr. 2014; (published online December 29) 10.1371/currents.outbreaks.b50c2aaf1032b3ccade0fca0b63ee518.
Delrieu I Yaro S Tamekloe TA et al. Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso. PLoS One. 2011; 6: e19513.
Sidikou F Zaneidou M Alkassoum I et al. Emergence of epidemic Neisseria meningitidis serogroup C in Niger, 2015: an analysis of national surveillance data. Lancet Infect Dis. 2016; 16: 1288-1294.
Standard operating procedures for enhanced meningitis surveillance in Africa, https://apps.who.int/iris/bitstream/handle/10665/312141/9789290234241-eng.pdf; 2019 [accessed 5 May 2019].
Cibrelus L, Lingani C, Fernandez K, Perea WA, Hugonnet S. Risk assessment and meningococcal A conjugate vaccine Introduction in Africa: The district prioritization tool. Clinical Infectious Diseases 2015; 61 (S5), S442-450. https://doi:10.1093/cid/civ671.
Browse journals by subject